


**AMENDMENTS TO THE CLAIMS**

1 (previously presented). A compound of Formula (I)



wherein

Ar is an unsubstituted or substituted aryl, or an unsubstituted or substituted heteroaryl;

$R^0$  is H, a hydroxy-protecting group, or taken together with  $R^1$  forms a five membered ring;

$R^1$  is H,  $(C_1-C_6)$ alkyl, an amino-protecting group, or taken together with  $R^0$  forms a five membered ring;

$R^2$ ,  $R^3$  and  $R^5$  are each independently H or  $(C_1-C_6)$ alkyl;

X is a covalent bond, O,  $S(O)_p$ , where p is 0, 1 or 2, or  $NR^{1a}$ , where  $R^{1a}$  is H or  $(C_1-C_6)$ alkyl;

$R^4$  for each occurrence is independently halo, unsubstituted or substituted  $(C_1-C_6)$ alkyl, cyano, or unsubstituted or substituted  $(C_1-C_6)$ alkoxy;

n is 0, 1, 2, or 3; and

$R^6$  and  $R^7$  are independently H, substituted or unsubstituted  $(C_1-C_6)$ alkyl, a substituted or unsubstituted, partially or fully saturated  $(C_3-C_8)$ cycloalkyl, a substituted or unsubstituted, partially or fully saturated  $(C_3-C_8)$  heterocyclic ring, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, or  $R^6$  and  $R^7$  taken together form a substituted or unsubstituted, partially or fully saturated, heterocyclic 3 to 8 membered ring;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

2(previously presented). The compound of Claim 1 wherein R<sup>1</sup> and R<sup>5</sup> are hydrogen, and n is 0; a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

3(previously presented). The compound of Claim 2 wherein Ar is pyridyl; a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

4(previously presented). The compound of Claim 3 wherein said pyridyl is 3-pyridyl; a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

5(previously presented). The compound of Claim 4 wherein R<sup>2</sup> and R<sup>3</sup> are hydrogen; a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

6(previously presented). The compound of Claim 4 wherein R<sup>2</sup> and R<sup>3</sup> are methyl; a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

7(previously presented). The compound of Claim 4 wherein X is a covalent bond; a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

8(previously presented). The compound of Claim 4 wherein X is an oxygen; a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

9(previously presented). The compound of Claim 5 wherein X is a covalent bond; a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

10(previously presented). The compound of Claim 5 wherein X is an oxygen; a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

11(previously presented). The compound of Claim 6 wherein X is a covalent bond; a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

12(previously presented). The compound of Claim 2 wherein said Ar is a substituted phenyl, said substituted phenyl being a halogen substituted phenyl; a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.


13(previously presented). The compound of Claim 12 wherein said halogen substituted phenyl is 3-chlorophenyl a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

14(previously presented). The compound of Claim 13 wherein X is a covalent bond; a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

15(previously presented). The compound of Claim 13 wherein R<sup>2</sup> and R<sup>3</sup> are hydrogen a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

16(previously presented). The compound of Claim 14 wherein R<sup>2</sup> and R<sup>3</sup> are hydrogen; a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

17(previously presented). A compound of Formula (IA)



wherein

Ar is an unsubstituted or substituted aryl, or an unsubstituted or substituted heteroaryl;

$R^0$  is H, a hydroxy-protecting group, or taken together with  $R^1$  forms a five membered ring;

$R^1$  is H, ( $C_1$ - $C_6$ )alkyl, an amino-protecting group, or taken together with  $R^0$  forms a five membered ring;

$R^2$ ,  $R^3$  and  $R^5$  are each independently H or ( $C_1$ - $C_6$ )alkyl;

$X$  is a covalent bond, O,  $S(O)_p$ , where  $p$  is 0, 1 or 2, or  $NR^{1a}$ , where  $R^{1a}$  is H or ( $C_1$ - $C_6$ )alkyl;

$R^4$  for each occurrence is independently halo, unsubstituted or substituted ( $C_1$ - $C_6$ )alkyl, cyano, or unsubstituted or substituted ( $C_1$ - $C_6$ )alkoxy;

$n$  is 0, 1, 2 or 3; and

$R^6$  and  $R^7$  are independently H, substituted or unsubstituted ( $C_1$ - $C_6$ )alkyl, a substituted or unsubstituted, partially or fully saturated ( $C_3$ - $C_8$ )cycloalkyl, a substituted or unsubstituted, partially or fully saturated ( $C_3$ - $C_8$ ) heterocyclic ring, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, or  $R^6$  and  $R^7$  taken together form a substituted or unsubstituted, partially or fully saturated, heterocyclic 3 to 8 membered ring;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

18(previously presented). The compound of Claim 17 wherein  $R^1$  and  $R^5$  are hydrogen and  $n$  is 0; a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

19(previously presented). The compound of Claim 18 wherein Ar is pyridyl; a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

20(previously presented). The compound of Claim 19 wherein said pyridyl is 3-pyridyl; a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

21(previously presented). The compound of Claim 20 wherein R<sup>2</sup> and R<sup>3</sup> are hydrogen; a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

22(previously presented). The compound of Claim 20 wherein R<sup>2</sup> and R<sup>3</sup> are methyl; a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

23(previously presented). The compound of Claim 20 wherein X is a covalent bond; a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

24(previously presented). The compound of Claim 20 wherein X is an oxygen; a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

25(previously presented). The compound of Claim 21 wherein X is a covalent bond; a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

26(previously presented). The compound of Claim 21 wherein X is an oxygen; a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

27(previously presented). The compound of Claim 22 wherein X is a covalent bond; a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

28(previously presented). The compound of Claim 18 wherein said Ar is a substituted phenyl, said substituted phenyl being a halogen substituted phenyl; a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

29(previously presented). The compound of Claim 28 wherein said halogen substituted phenyl is 3-chlorophenyl; a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

30(previously presented). The compound of Claim 29 wherein X is a covalent bond; a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

31(previously presented). The compound of Claim 29 wherein R<sup>2</sup> and R<sup>3</sup> are hydrogen; a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

32(previously presented). The compound of Claim 30 wherein R<sup>2</sup> and R<sup>3</sup> are hydrogen; a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

33(previously presented). The compound of Claim 30 wherein R<sup>2</sup> and R<sup>3</sup> are methyl; a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

34(previously presented). A compound selected from the group consisting of

*N*-[4-[2-[(2*R*)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-2-methylpropyl]phenyl]-1-piperidinesulfonamide;

[4-[2-[(2*R*)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl] - phenyl]trimethyl-sulfamide;

*N'*-[4-[2-[(2*R*)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]- phenyl]-*N,N*-dimethyl-sulfamide;

*N*-[4-[2-[(2*R*)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-1-piperidinesulfonamide;

*N*-[4-[2-[(2*R*)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-*N'*-cyclohexyl-sulfamide;

*N'*-[4-[2-[(2*R*)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]- phenyl]-*N*-cyclohexyl-*N*-methyl-sulfamide;

*N*-(cyclopropylmethyl)-*N'*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]-amino]-2-methylpropyl]phenyl]-sulfamide;

*N*-(1,1-dimethyl-2-phenylethyl)-*N'*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]-amino]-2-methylpropyl]phenyl]-sulfamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]-phenyl]-2,6-dimethyl-, (2*R*,6*S*)-4-morpholinesulfonamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]phenyl]-4-methyl-1-piperidinesulfonamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]-phenyl]-3,5-dimethyl-, (3*R*,5*S*)-1-piperidinesulfonamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]phenyl]-4-phenyl-1-piperidinesulfonamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]phenyl]-*N'*-(1*S*)-1-phenylethyl]-sulfamide;

*N*-cyclohexyl-*N'*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]phenyl]-sulfamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]-phenyl]-octahydro-(4*aR*,8*aR*)-2(1*H*)-isoquinolinesulfonamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]phenyl]-*N'*-phenyl-sulfamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]phenyl]-*N,N*-dimethyl-sulfamide;

*N*-(cyclohexylmethyl)-*N'*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]phenyl]-sulfamide;

*N*-cyclopropyl-*N'*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]phenyl]-sulfamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]-phenyl]-3-methyl-3-phenyl-1-piperidinesulfonamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]phenyl]-3,3-dimethyl-1-piperidinesulfonamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]-phenyl]-2,3-dihydro-spiro[1*H*-indene-1,3'-piperidine]-1'-sulfonamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]-phenyl]-*N'*-[(1*R*,2*S*)-2-phenylcyclopropyl]-sulfamide;

*N*-(2,3-dihydro-1*H*-inden-1-yl)-*N'*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]phenyl]- sulfamide;

*N*-(1*R*,2*S*,4*S*)-*endo*-bicyclo[2.2.1]hept-2-yl-*N'*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]phenyl]-sulfamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]phenyl]-*N'*-(2-methoxyethyl)-sulfamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]-phenyl]-*N'*-[(2*S*)-tetrahydro-2-furanyl]methyl]-sulfamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]phenyl]-4-methyl-1-piperazinesulfonamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]-phenyl]-4-(phenylmethyl)-1-piperazinesulfonamide;

*N*-cyclobutyl-*N*'-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]phenyl]-sulfamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]phenyl]-1-piperazinesulfonamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]-phenyl]-*N*'-[1-(phenylmethyl)-4-piperidinyl]-sulfamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]-phenyl]-*N*'-[(3*S*)-1-(phenylmethyl)-3-pyrrolidinyl]-sulfamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]-phenyl]-*N*'-[(1*S,2S*)-2-(phenylmethoxy)cyclopentyl]-sulfamide;

*N*'-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-*N,N*-dimethyl-sulfamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-1-piperidinesulfonamide;

*N*-cyclohexyl-*N*'-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-ethyl]phenyl]-*N*-methyl-sulfamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-(phenylmethyl)-1-piperidinesulfonamide;

*N*-[4-[2-[(2*R*)-2-Hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-methyl-1-piperidinesulfonamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-hexahydro-1*H*-azepine-1-sulfonamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-2,6-dimethyl-, (2*R,6S*)-4-morpholinesulfonamide;

*N*'-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-*N*-methyl-*N*-(2-phenylethyl)-sulfamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-*N*-methyl-*N*-(1-methylethyl)-sulfamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-3,4-dihydro-2(1*H*)-isoquinolinesulfonamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-2-(methoxymethyl)-, (2*S*)-1-pyrrolidinesulfonamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-3,5-dimethyl-, (3*R*,5*S*)-1piperidinesulfonamide;

*N*-(2,3-dihydro-1*H*-inden-2-yl)-*N*'-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-sulfamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-phenyl-1-piperidinesulfonamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-*N*-methyl-*N*-phenyl-sulfamide;

4-(1,1-dimethylethyl)-*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-1-piperidinesulfonamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-octahydro-(4a*S*,8a*S*)-2(1*H*)-isoquinolinesulfonamide;

*N*-cyclohexyl-*N*'-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-sulfamide;

3-cyclohexyl-*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-1-piperidinesulfonamide;

4-cyano-*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-phenyl-1-piperidinesulfonamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-3-[(4-methoxyphenyl)methyl]-1-pyrrolidinesulfonamide;

*N*-[(1*R*,2*S*,4*S*)-*endo*-bicyclo[2.2.1]hept-2-ylmethyl]-*N*'-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]2-methylpropyl]phenyl]-sulfamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-5-methoxy-3,4-dihydro-spiro[naphthalene-1(2*H*),4'-piperidine]-1'-sulfonamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane-3-sulfonamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-7-(trifluoromethyl)-1,2,4,5-tetrahydro-1,5-methano-3*H*-3-benzazepine-3-sulfonamide;

*N'*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethoxy]phenyl]-*N,N*-dimethyl-sulfamide; and

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethoxy]phenyl]-4-methyl-1-piperidinesulfonamide;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

35(previously presented). A compound selected from the group consisting of

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]phenyl]-2*R*,6*S*-dimethyl-4-morpholinesulfonamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-2(*S*)-(methoxymethyl)-1-pyrrolidinesulfonamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-3,5-dimethyl-, (3*R*,5*S*)-1-piperidinesulfonamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]phenyl]-3,5-dimethyl-, (3*R*,5*S*)-1-piperidinesulfonamide;

*N*-cyclohexyl-*N'*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]phenyl]-sulfamide;

*N*-cyclopropyl-*N'*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]phenyl]-sulfamide;

*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]phenyl]-3-methyl-3-phenyl-1-piperidinesulfonamide;


*N*-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]phenyl]-3,3-dimethyl-1-piperidinesulfonamide;

*N*-(cyclopropylmethyl)-*N*'-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]phenyl]-sulfamide; and

*N*-(1*R*,2*S*,4*S*)-*endo*-bicyclo[2.2.1]hept-2-yl-*N*'-[4-[2-[(2*R*)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]phenyl]-sulfamide;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

36(previously presented). A compound of Formula (I)



wherein

Ar is an unsubstituted or substituted aryl, or an unsubstituted or substituted heteroaryl;

R<sup>0</sup> and R<sup>1</sup> are hydrogen;

R<sup>2</sup>, R<sup>3</sup> and R<sup>5</sup> are each independently H or (C<sub>1</sub>-C<sub>6</sub>)alkyl;


X is a covalent bond, O, S(O)<sub>p</sub>, where p is 0, 1 or 2, or NR<sup>1a</sup>, where R<sup>1a</sup> is H or (C<sub>1</sub>-C<sub>6</sub>)alkyl;

R<sup>4</sup> for each occurrence is independently halo, unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub>)alkyl, cyano, or unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub>)alkoxy;

n is 0, 1, 2, or 3; and


R<sup>6</sup> and R<sup>7</sup> are independently H, substituted or unsubstituted (C<sub>1</sub>-C<sub>6</sub>)alkyl, a substituted or unsubstituted, partially or fully saturated (C<sub>3</sub>-C<sub>8</sub>)cycloalkyl, a substituted or unsubstituted, partially or fully saturated (C<sub>3</sub>-C<sub>8</sub>)heterocyclic ring, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, or R<sup>6</sup> and R<sup>7</sup> taken together form a substituted or unsubstituted, partially or fully saturated, heterocyclic 3 to 8 membered ring;

prepared by deprotecting a compound of Formula (II)



wherein  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $Ar$ ,  $X$ , and  $n$  are as defined above.

37(previously presented). A compound of Formula (I)



wherein

$Ar$  is an unsubstituted or substituted aryl, or an unsubstituted or substituted heteroaryl;

$R^0$  and  $R^1$  are hydrogen;

$R^2$ ,  $R^3$  and  $R^5$  are each independently H or  $(C_1-C_6)$ alkyl;


$X$  is a covalent bond, O,  $S(O)_p$ , where  $p$  is 0, 1 or 2, or  $NR^{1a}$ , where  $R^{1a}$  is H or  $(C_1-C_6)$ alkyl;

$R^4$  for each occurrence is independently halo, unsubstituted or substituted  $(C_1-C_6)$ alkyl, cyano, or unsubstituted or substituted  $(C_1-C_6)$ alkoxy;

$n$  is 0, 1, 2, or 3; and


$R^6$  and  $R^7$  are independently H, substituted or unsubstituted  $(C_1-C_6)$ alkyl, a substituted or unsubstituted, partially or fully saturated  $(C_3-C_8)$ cycloalkyl, a substituted or unsubstituted, partially or fully saturated  $(C_3-C_8)$  heterocyclic ring, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, or  $R^6$  and  $R^7$  taken together form a substituted or unsubstituted, partially or fully saturated, heterocyclic 3 to 8 membered ring;

prepared by deprotecting a compound of Formula (III)



wherein  $R^0$  is a hydroxy-protecting group;  $R^1$  is H or an amino-protecting group; and  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $Ar$ ,  $X$ , and  $n$  are as defined above.

38(currently amended). A method of treating a  $\beta_3$  adrenergic receptor-mediated disease, condition, or disorder in an animal in need of such treatment comprising the step of administering to said animal a therapeutically effective amount of a compound of Formula (I)



wherein

$Ar$  is an unsubstituted or substituted aryl, or an unsubstituted or substituted heteroaryl;

$R^1$ ,  $R^2$ ,  $R^3$  and  $R^5$  are each independently H or  $(C_1-C_6)$ alkyl;

$X$  is a covalent bond, O,  $S(O)_p$ , where  $p$  is 0, 1 or 2, or  $NR^{1a}$ , where  $R^{1a}$  is H or  $(C_1-C_6)$ alkyl;

$R^4$  for each occurrence is independently halo, unsubstituted or substituted  $(C_1-C_6)$ alkyl, cyano, or unsubstituted or substituted  $(C_1-C_6)$ alkoxy;

$n$  is 0, 1, 2, or 3; and


$R^6$  and  $R^7$  are independently H, substituted or unsubstituted  $(C_1-C_6)$ alkyl, a substituted or unsubstituted, partially or fully saturated  $(C_3-C_8)$ cycloalkyl, a substituted or unsubstituted, partially or fully saturated  $(C_3-C_8)$  heterocyclic ring, a

substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, or R<sup>6</sup> and R<sup>7</sup> taken together form a substituted or unsubstituted, partially or fully saturated, heterocyclic 3 to 8 membered ring;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt,

wherein said β<sub>3</sub> adrenergic receptor-mediated disease, condition, or disorder is selected from the group consisting of obesity, diabetes, irritable bowel syndrome, inflammatory bowel disease, esophagitis, duodenitis, Crohn's Disease, proctitis, asthma, intestinal motility disorder, ulcer, gastritis, hypercholesterolemia, cardiovascular disease, urinary incontinence, depression, prostate disease, dyslipidemia, and airway inflammatory disorder.

39(currently amended). The method of Claim 38 wherein said compound of Formula (I) is a compound of Formula (IA)



wherein

Ar is an unsubstituted or substituted aryl, or an unsubstituted or substituted heteroaryl;

R<sup>1</sup> is hydrogen;

R<sup>2</sup>, R<sup>3</sup> and R<sup>5</sup> are each independently H or (C<sub>1</sub>-C<sub>6</sub>)alkyl;

X is a covalent bond, O, S(O)<sub>p</sub>, where p is 0, 1 or 2, or NR<sup>1a</sup>, where R<sup>1a</sup> is H or (C<sub>1</sub>-C<sub>6</sub>)alkyl;

R<sup>4</sup> for each occurrence is independently halo, unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub>)alkyl, cyano, or unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub>)alkoxy;

n is 0, 1, 2, or 3; and


$R^6$  and  $R^7$  are independently H, substituted or unsubstituted ( $C_1$ - $C_6$ )alkyl, a substituted or unsubstituted, partially or fully saturated ( $C_3$ - $C_8$ )cycloalkyl, a substituted or unsubstituted, partially or fully saturated ( $C_3$ - $C_8$ ) heterocyclic ring, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, or  $R^6$  and  $R^7$  taken together form a substituted or unsubstituted, partially or fully saturated, heterocyclic 3 to 8 membered ring;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt,

wherein said  $\beta_3$  adrenergic receptor-mediated disease, condition, or disorder is selected from the group consisting of obesity, diabetes, irritable bowel syndrome, inflammatory bowel disease, esophagitis, duodenitis, Crohn's Disease, proctitis, asthma, intestinal motility disorder, ulcer, gastritis, hypercholesterolemia, cardiovascular disease, urinary incontinence, depression, prostate disease, dyslipidemia, and airway inflammatory disorder.

40(cancelled).

41(previously presented). A method of increasing lean meat content in an edible animal comprising the step of administering to said edible animal a lean meat increasing amount of a compound of Formula (I)



wherein

$Ar$  is an unsubstituted or substituted aryl, or an unsubstituted or substituted heteroaryl;

$R^1$ ,  $R^2$ ,  $R^3$  and  $R^5$  are each independently H or ( $C_1$ - $C_6$ )alkyl;

X is a covalent bond, O, S(O)<sub>p</sub>, where p is 0, 1 or 2, or NR<sup>1a</sup>, where R<sup>1a</sup> is H or (C<sub>1</sub>-C<sub>6</sub>)alkyl;


R<sup>4</sup> for each occurrence is independently halo, unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub>)alkyl, cyano, or unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub>)alkoxy;

n is 0, 1, 2, or 3; and

R<sup>6</sup> and R<sup>7</sup> are independently H, substituted or unsubstituted (C<sub>1</sub>-C<sub>6</sub>)alkyl, a substituted or unsubstituted, partially or fully saturated (C<sub>3</sub>-C<sub>8</sub>)cycloalkyl, a substituted or unsubstituted, partially or fully saturated (C<sub>3</sub>-C<sub>8</sub>) heterocyclic ring, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, or R<sup>6</sup> and R<sup>7</sup> taken together form a substituted or unsubstituted, partially or fully saturated, heterocyclic 3 to 8 membered ring;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

42(previously presented). The method of Claim 41 wherein said compound of Formula (I) is a compound of Formula (IA)



wherein

Ar is an unsubstituted or substituted aryl, or an unsubstituted or substituted heteroaryl;

R<sup>1</sup> is hydrogen;

R<sup>2</sup>, R<sup>3</sup> and R<sup>5</sup> are each independently H or (C<sub>1</sub>-C<sub>6</sub>)alkyl;

X is a covalent bond, O, S(O)<sub>p</sub>, where p is 0, 1 or 2, or NR<sup>1a</sup>, where R<sup>1a</sup> is H or (C<sub>1</sub>-C<sub>6</sub>)alkyl;

R<sup>4</sup> for each occurrence is independently halo, unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub>)alkyl, cyano, or unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub>)alkoxy;


n is 0, 1, 2, or 3; and

R<sup>6</sup> and R<sup>7</sup> are independently H, substituted or unsubstituted (C<sub>1</sub>-C<sub>6</sub>)alkyl, a substituted or unsubstituted, partially or fully saturated (C<sub>3</sub>-C<sub>8</sub>)cycloalkyl, a substituted or unsubstituted, partially or fully saturated (C<sub>3</sub>-C<sub>8</sub>) heterocyclic ring, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, or R<sup>6</sup> and R<sup>7</sup> taken together form a substituted or unsubstituted, partially or fully saturated, heterocyclic 3 to 8 membered ring;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

43(previously presented). A pharmaceutical composition comprising

- (a) a pharmaceutically acceptable carrier, vehicle, diluent or mixture thereof; and
- (b) a compound of Formula (I)



wherein

Ar is an unsubstituted or substituted aryl, or an unsubstituted or substituted heteroaryl;

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>5</sup> are each independently H or (C<sub>1</sub>-C<sub>6</sub>)alkyl;

X is a covalent bond, O, S(O)<sub>p</sub>, where p is 0, 1 or 2, or NR<sup>1a</sup>, where R<sup>1a</sup> is H or (C<sub>1</sub>-C<sub>6</sub>)alkyl;

R<sup>4</sup> for each occurrence is independently halo, unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub>)alkyl, cyano, or unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub>)alkoxy;


n is 0, 1, 2, or 3; and

R<sup>6</sup> and R<sup>7</sup> are independently H, substituted or unsubstituted (C<sub>1</sub>-C<sub>6</sub>)alkyl, a substituted or unsubstituted, partially or fully saturated (C<sub>3</sub>-C<sub>8</sub>)cycloalkyl, a

substituted or unsubstituted, partially or fully saturated ( $C_3$ - $C_8$ ) heterocyclic ring, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, or  $R^6$  and  $R^7$  taken together form a substituted or unsubstituted, partially or fully saturated, heterocyclic 3 to 8 membered ring;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

44(previously presented). The composition of Claim 43 wherein said compound of Formula (I) is a compound of Formula (IA)



wherein

$Ar$  is an unsubstituted or substituted aryl, or an unsubstituted or substituted heteroaryl;

$R^1$ ,  $R^2$ ,  $R^3$  and  $R^5$  are each independently H or ( $C_1$ - $C_6$ )alkyl;

$X$  is a covalent bond, O,  $S(O)_p$ , where  $p$  is 0, 1 or 2, or  $NR^{1a}$ , where  $R^{1a}$  is H or ( $C_1$ - $C_6$ )alkyl;

$R^4$  for each occurrence is independently halo, unsubstituted or substituted ( $C_1$ - $C_6$ )alkyl, cyano, or unsubstituted or substituted ( $C_1$ - $C_6$ )alkoxy;

$n$  is 0, 1, 2, or 3; and

$R^6$  and  $R^7$  are independently H, substituted or unsubstituted ( $C_1$ - $C_6$ )alkyl, a substituted or unsubstituted, partially or fully saturated ( $C_3$ - $C_8$ )cycloalkyl, a substituted or unsubstituted, partially or fully saturated ( $C_3$ - $C_8$ ) heterocyclic ring, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, or  $R^6$  and  $R^7$  taken together form a substituted or unsubstituted, partially or fully saturated, heterocyclic 3 to 8 membered ring;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

Claims 45-48 (cancelled).

49(currently amended). A method of treating a  $\beta_3$  adrenergic receptor-mediated disease, condition, or disorder in an animal in need of such treatment comprising the step of administering to said animal a therapeutically effective amount of a composition of claim 43,

. wherein said  $\beta_3$  adrenergic receptor-mediated disease, condition, or disorder is selected from the group consisting of obesity, diabetes, irritable bowel syndrome, inflammatory bowel disease, esophagitis, duodenitis, Crohn's Disease, proctitis, asthma, intestinal motility disorder, ulcer, gastritis, hypercholesterolemia, cardiovascular disease, urinary incontinence, depression, prostate disease, dyslipidemia, and airway inflammatory disorder.

50(currently amended). A method of treating a  $\beta_3$  adrenergic receptor-mediated disease, condition, or disorder in an animal in need of such treatment comprising the step of administering to said animal a therapeutically effective amount of a composition of claim 44,

wherein said  $\beta_3$  adrenergic receptor-mediated disease, condition, or disorder is selected from the group consisting of obesity, diabetes, irritable bowel syndrome, inflammatory bowel disease, esophagitis, duodenitis, Crohn's Disease, proctitis, asthma, intestinal motility disorder, ulcer, gastritis, hypercholesterolemia, cardiovascular disease, urinary incontinence, depression, prostate disease, dyslipidemia, and airway inflammatory disorder.

Claims 51-56 (cancelled).

57(original). A method of increasing lean meat content in an edible animal comprising the step of administering to said edible animal a lean meat increasing amount of a pharmaceutical composition of Claim 43.

58(original). A method of increasing lean meat content in an edible animal comprising the step of administering to said edible animal a lean meat increasing amount of a pharmaceutical composition of Claim 44.

Claims 59-69 (cancelled).